Research Highlight |
Featured
-
-
Research Highlight |
Androgen suppression duration and zoledronic acid: under the RADAR
- Lisa Hutchinson
-
In Brief |
Denosumab—new treatment option for GCTB
-
Year in Review |
Prevention and treatment of bone metastases
Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.
- Robert E. Coleman